+357 96 030922
info@marketpublishers.com

Global Granulomatosis with Polyangiitis Drug Market Growth 2025-2031

https://marketpublishers.com/r/G752D5D30F93EN.html
Date: January 2025
Pages: 100
Price: US$ 3,660.00 (Single User License)
ID: G752D5D30F93EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Granulomatosis with Polyangiitis Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the “Granulomatosis with Polyangiitis Drug Industry Forecast” looks at past sales and reviews total world Granulomatosis with Polyangiitis Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Granulomatosis with Polyangiitis Drug

+357 96 030922
info@marketpublishers.com

sales for 2025 through 2031. With Granulomatosis with Polyangiitis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Granulomatosis with Polyangiitis Drug industry.

This Insight Report provides a comprehensive analysis of the global Granulomatosis with Polyangiitis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Granulomatosis with Polyangiitis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Granulomatosis with Polyangiitis Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Granulomatosis with Polyangiitis Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Granulomatosis with Polyangiitis Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Granulomatosis with Polyangiitis Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Benralizumab

Avacopan

Rituximab Biosimilar

Others

Segmentation by Application:

Hospital

+357 96 030922
info@marketpublishers.com

Clinic

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

+357 96 030922
info@marketpublishers.com

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Bionovis SA

Bristol-Myers Squibb Company

ChemoCentryx Inc

Coherus BioSciences Inc

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

Iltoo Pharma

Panacea Biotec Ltd

Sandoz International GmbH

+357 96 030922
info@marketpublishers.com

The International Biotechnology Center (IBC) Generium

Key Questions Addressed in this Report

What is the 10-year outlook for the global Granulomatosis with Polyangiitis Drug market?

What factors are driving Granulomatosis with Polyangiitis Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Granulomatosis with Polyangiitis Drug market opportunities vary by end market size?

How does Granulomatosis with Polyangiitis Drug break out by Type, by Application?

+357 96 030922
info@marketpublishers.com

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Granulomatosis with Polyangiitis Drug by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Granulomatosis with Polyangiitis Drug by Country/Region, 2020, 2024 & 2031
2.2 Granulomatosis with Polyangiitis Drug Segment by Type
  2.2.1 Benralizumab
  2.2.2 Avacopan
  2.2.3 Rituximab Biosimilar
  2.2.4 Others
2.3 Granulomatosis with Polyangiitis Drug Sales by Type
  2.3.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2020-2025)
  2.3.2 Global Granulomatosis with Polyangiitis Drug Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Type (2020-2025)
2.4 Granulomatosis with Polyangiitis Drug Segment by Application
  2.4.1 Hospital
  2.4.2 Clinic
  2.4.3 Others
2.5 Granulomatosis with Polyangiitis Drug Sales by Application
  2.5.1 Global Granulomatosis with Polyangiitis Drug Sale Market Share by Application (2020-2025)

+357 96 030922
info@marketpublishers.com

2.5.2 Global Granulomatosis with Polyangiitis Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Granulomatosis with Polyangiitis Drug Breakdown Data by Company
3.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Company (2020-2025)
3.1.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2020-2025)
3.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Company (2020-2025)
3.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company (2020-2025)
3.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Company
3.4 Key Manufacturers Granulomatosis with Polyangiitis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Granulomatosis with Polyangiitis Drug Product Location Distribution
3.4.2 Players Granulomatosis with Polyangiitis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR GRANULOMATOSIS WITH POLYANGIITIS DRUG BY GEOGRAPHIC REGION

4.1 World Historic Granulomatosis with Polyangiitis Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Granulomatosis with Polyangiitis Drug Market Size by

+357 96 030922
info@marketpublishers.com

Country/Region (2020-2025)
4.2.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Granulomatosis with Polyangiitis Drug Sales Growth
4.4 APAC Granulomatosis with Polyangiitis Drug Sales Growth
4.5 Europe Granulomatosis with Polyangiitis Drug Sales Growth
4.6 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Growth

5 AMERICAS

5.1 Americas Granulomatosis with Polyangiitis Drug Sales by Country
5.1.1 Americas Granulomatosis with Polyangiitis Drug Sales by Country (2020-2025)
5.1.2 Americas Granulomatosis with Polyangiitis Drug Revenue by Country (2020-2025)
5.2 Americas Granulomatosis with Polyangiitis Drug Sales by Type (2020-2025)
5.3 Americas Granulomatosis with Polyangiitis Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Granulomatosis with Polyangiitis Drug Sales by Region
6.1.1 APAC Granulomatosis with Polyangiitis Drug Sales by Region (2020-2025)
6.1.2 APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2020-2025)
6.2 APAC Granulomatosis with Polyangiitis Drug Sales by Type (2020-2025)
6.3 APAC Granulomatosis with Polyangiitis Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

+357 96 030922
info@marketpublishers.com

7.1 Europe Granulomatosis with Polyangiitis Drug by Country
7.1.1 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2020-2025)
7.1.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2020-2025)
7.2 Europe Granulomatosis with Polyangiitis Drug Sales by Type (2020-2025)
7.3 Europe Granulomatosis with Polyangiitis Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Granulomatosis with Polyangiitis Drug by Country
8.1.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug

+357 96 030922
info@marketpublishers.com

10.3 Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
10.4 Industry Chain Structure of Granulomatosis with Polyangiitis Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Granulomatosis with Polyangiitis Drug Distributors
11.3 Granulomatosis with Polyangiitis Drug Customer

12 WORLD FORECAST REVIEW FOR GRANULOMATOSIS WITH POLYANGIITIS DRUG BY GEOGRAPHIC REGION

12.1 Global Granulomatosis with Polyangiitis Drug Market Size Forecast by Region
  12.1.1 Global Granulomatosis with Polyangiitis Drug Forecast by Region (2026-2031)
  12.1.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Granulomatosis with Polyangiitis Drug Forecast by Type (2026-2031)
12.7 Global Granulomatosis with Polyangiitis Drug Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Bionovis SA
  13.1.1 Bionovis SA Company Information
  13.1.2 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
  13.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Bionovis SA Main Business Overview
  13.1.5 Bionovis SA Latest Developments
13.2 Bristol-Myers Squibb Company
  13.2.1 Bristol-Myers Squibb Company Company Information
  13.2.2 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications

+357 96 030922
info@marketpublishers.com

13.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Bristol-Myers Squibb Company Main Business Overview
13.2.5 Bristol-Myers Squibb Company Latest Developments
13.3 ChemoCentryx Inc
13.3.1 ChemoCentryx Inc Company Information
13.3.2 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 ChemoCentryx Inc Main Business Overview
13.3.5 ChemoCentryx Inc Latest Developments
13.4 Coherus BioSciences Inc
13.4.1 Coherus BioSciences Inc Company Information
13.4.2 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Coherus BioSciences Inc Main Business Overview
13.4.5 Coherus BioSciences Inc Latest Developments
13.5 Genor BioPharma Co Ltd
13.5.1 Genor BioPharma Co Ltd Company Information
13.5.2 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Genor BioPharma Co Ltd Main Business Overview
13.5.5 Genor BioPharma Co Ltd Latest Developments
13.6 GlaxoSmithKline Plc
13.6.1 GlaxoSmithKline Plc Company Information
13.6.2 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 GlaxoSmithKline Plc Main Business Overview
13.6.5 GlaxoSmithKline Plc Latest Developments
13.7 Iltoo Pharma
13.7.1 Iltoo Pharma Company Information
13.7.2 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolios and

+357 96 030922
info@marketpublishers.com

Specifications
13.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Iltoo Pharma Main Business Overview
13.7.5 Iltoo Pharma Latest Developments
13.8 Panacea Biotec Ltd
13.8.1 Panacea Biotec Ltd Company Information
13.8.2 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Panacea Biotec Ltd Main Business Overview
13.8.5 Panacea Biotec Ltd Latest Developments
13.9 Sandoz International GmbH
13.9.1 Sandoz International GmbH Company Information
13.9.2 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Sandoz International GmbH Main Business Overview
13.9.5 Sandoz International GmbH Latest Developments
13.10 The International Biotechnology Center (IBC) Generium
13.10.1 The International Biotechnology Center (IBC) Generium Company Information
13.10.2 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
13.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 The International Biotechnology Center (IBC) Generium Main Business Overview
13.10.5 The International Biotechnology Center (IBC) Generium Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OFTABLES

Table 1. Granulomatosis with Polyangiitis Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Granulomatosis with Polyangiitis Drug Annual Sales CAGR by Country/Region

+357 96 030922
info@marketpublishers.com

(2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Benralizumab
Table 4. Major Players of Avacopan
Table 5. Major Players of Rituximab Biosimilar
Table 6. Major Players of Others
Table 7. Global Granulomatosis with Polyangiitis Drug Sales byType (2020-2025) & (K Pcs)
Table 8. Global Granulomatosis with Polyangiitis Drug Sales Market Share byType (2020-2025)
Table 9. Global Granulomatosis with Polyangiitis Drug Revenue byType (2020-2025) & ($ million)
Table 10. Global Granulomatosis with Polyangiitis Drug Revenue Market Share byType (2020-2025)
Table 11. Global Granulomatosis with Polyangiitis Drug Sale Price byType (2020-2025) & (USD/Pcs)
Table 12. Global Granulomatosis with Polyangiitis Drug Sale by Application (2020-2025) & (K Pcs)
Table 13. Global Granulomatosis with Polyangiitis Drug Sale Market Share by Application (2020-2025)
Table 14. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2020-2025) & ($ million)
Table 15. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2020-2025)
Table 16. Global Granulomatosis with Polyangiitis Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 17. Global Granulomatosis with Polyangiitis Drug Sales by Company (2020-2025) & (K Pcs)
Table 18. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2020-2025)
Table 19. Global Granulomatosis with Polyangiitis Drug Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company (2020-2025)
Table 21. Global Granulomatosis with Polyangiitis Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 22. Key Manufacturers Granulomatosis with Polyangiitis Drug Producing Area Distribution and Sales Area
Table 23. Players Granulomatosis with Polyangiitis Drug Products Offered
Table 24. Granulomatosis with Polyangiitis Drug Concentration Ratio (CR3, CR5 and

+357 96 030922
info@marketpublishers.com

CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Granulomatosis with Polyangiitis Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 28. Global Granulomatosis with Polyangiitis Drug Sales Market Share Geographic Region (2020-2025)
Table 29. Global Granulomatosis with Polyangiitis Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Granulomatosis with Polyangiitis Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 32. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Country/Region (2020-2025)
Table 33. Global Granulomatosis with Polyangiitis Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Granulomatosis with Polyangiitis Drug Sales by Country (2020-2025) & (K Pcs)
Table 36. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2020-2025)
Table 37. Americas Granulomatosis with Polyangiitis Drug Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Granulomatosis with Polyangiitis Drug Sales byType (2020-2025) & (K Pcs)
Table 39. Americas Granulomatosis with Polyangiitis Drug Sales by Application (2020-2025) & (K Pcs)
Table 40. APAC Granulomatosis with Polyangiitis Drug Sales by Region (2020-2025) & (K Pcs)
Table 41. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2020-2025)
Table 42. APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Granulomatosis with Polyangiitis Drug Sales byType (2020-2025) & (K Pcs)
Table 44. APAC Granulomatosis with Polyangiitis Drug Sales by Application (2020-2025) & (K Pcs)

+357 96 030922
info@marketpublishers.com

Table 45. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2020-2025) & (K Pcs)
Table 46. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Granulomatosis with Polyangiitis Drug Sales byType (2020-2025) & (K Pcs)
Table 48. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2020-2025) & (K Pcs)
Table 49. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales byType (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application (2020-2025) & (K Pcs)
Table 53. Key Market Drivers & Growth Opportunities of Granulomatosis with Polyangiitis Drug
Table 54. Key Market Challenges & Risks of Granulomatosis with Polyangiitis Drug
Table 55. Key IndustryTrends of Granulomatosis with Polyangiitis Drug
Table 56. Granulomatosis with Polyangiitis Drug Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Granulomatosis with Polyangiitis Drug Distributors List
Table 59. Granulomatosis with Polyangiitis Drug Customer List
Table 60. Global Granulomatosis with Polyangiitis Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 61. Global Granulomatosis with Polyangiitis Drug RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas Granulomatosis with Polyangiitis Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 63. Americas Granulomatosis with Polyangiitis Drug Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC Granulomatosis with Polyangiitis Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 65. APAC Granulomatosis with Polyangiitis Drug Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe Granulomatosis with Polyangiitis Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 67. Europe Granulomatosis with Polyangiitis Drug RevenueForecast by Country

+357 96 030922
info@marketpublishers.com

(2026-2031) & ($ millions)
Table 68. Middle East & Africa Granulomatosis with Polyangiitis Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 69. Middle East & Africa Granulomatosis with Polyangiitis Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global Granulomatosis with Polyangiitis Drug SalesForecast byType (2026-2031) & (K Pcs)
Table 71. Global Granulomatosis with Polyangiitis Drug RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global Granulomatosis with Polyangiitis Drug SalesForecast by Application (2026-2031) & (K Pcs)
Table 73. Global Granulomatosis with Polyangiitis Drug RevenueForecast by Application (2026-2031) & ($ millions)
Table 74. Bionovis SA Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 76. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 77. Bionovis SA Main Business
Table 78. Bionovis SA Latest Developments
Table 79. Bristol-Myers Squibb Company Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 81. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 82. Bristol-Myers Squibb Company Main Business
Table 83. Bristol-Myers Squibb Company Latest Developments
Table 84. ChemoCentryx Inc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 86. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 87. ChemoCentryx Inc Main Business
Table 88. ChemoCentryx Inc Latest Developments
Table 89. Coherus BioSciences Inc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

+357 96 030922
info@marketpublishers.com

Table 90. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 91. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 92. Coherus BioSciences Inc Main Business
Table 93. Coherus BioSciences Inc Latest Developments
Table 94. Genor BioPharma Co Ltd Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 96. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 97. Genor BioPharma Co Ltd Main Business
Table 98. Genor BioPharma Co Ltd Latest Developments
Table 99. GlaxoSmithKline Plc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 101. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 102. GlaxoSmithKline Plc Main Business
Table 103. GlaxoSmithKline Plc Latest Developments
Table 104. Iltoo Pharma Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 106. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 107. Iltoo Pharma Main Business
Table 108. Iltoo Pharma Latest Developments
Table 109. Panacea Biotec Ltd Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 111. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 112. Panacea Biotec Ltd Main Business
Table 113. Panacea Biotec Ltd Latest Developments
Table 114. Sandoz International GmbH Basic Information, Granulomatosis with

+357 96 030922
info@marketpublishers.com

Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 116. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 117. Sandoz International GmbH Main Business
Table 118. Sandoz International GmbH Latest Developments
Table 119.The International Biotechnology Center (IBC) Generium Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors
Table 120.The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolios and Specifications
Table 121.The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 122.The International Biotechnology Center (IBC) Generium Main Business
Table 123.The International Biotechnology Center (IBC) Generium Latest Developments

LIST OFFIGURES

Figure 1. Picture of Granulomatosis with Polyangiitis Drug
Figure 2. Granulomatosis with Polyangiitis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Granulomatosis with Polyangiitis Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Granulomatosis with Polyangiitis Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Granulomatosis with Polyangiitis Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Granulomatosis with Polyangiitis Drug Sales Market Share by Country/Region (2024)
Figure 10. Granulomatosis with Polyangiitis Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Benralizumab

+357 96 030922
info@marketpublishers.com

Figure 12. Product Picture of Avacopan
Figure 13. Product Picture of Rituximab Biosimilar
Figure 14. Product Picture of Others
Figure 15. Global Granulomatosis with Polyangiitis Drug Sales Market Share byType in 2025
Figure 16. Global Granulomatosis with Polyangiitis Drug Revenue Market Share byType (2020-2025)
Figure 17. Granulomatosis with Polyangiitis Drug Consumed in Hospital
Figure 18. Global Granulomatosis with Polyangiitis Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 19. Granulomatosis with Polyangiitis Drug Consumed in Clinic
Figure 20. Global Granulomatosis with Polyangiitis Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 21. Granulomatosis with Polyangiitis Drug Consumed in Others
Figure 22. Global Granulomatosis with Polyangiitis Drug Market: Others (2020-2025) & (K Pcs)
Figure 23. Global Granulomatosis with Polyangiitis Drug Sale Market Share by Application (2024)
Figure 24. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application in 2025
Figure 25. Granulomatosis with Polyangiitis Drug Sales by Company in 2025 (K Pcs)
Figure 26. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company in 2025
Figure 27. Granulomatosis with Polyangiitis Drug Revenue by Company in 2025 ($ millions)
Figure 28. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company in 2025
Figure 29. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Granulomatosis with Polyangiitis Drug Sales 2020-2025 (K Pcs)
Figure 32. Americas Granulomatosis with Polyangiitis Drug Revenue 2020-2025 ($ millions)
Figure 33. APAC Granulomatosis with Polyangiitis Drug Sales 2020-2025 (K Pcs)
Figure 34. APAC Granulomatosis with Polyangiitis Drug Revenue 2020-2025 ($ millions)
Figure 35. Europe Granulomatosis with Polyangiitis Drug Sales 2020-2025 (K Pcs)
Figure 36. Europe Granulomatosis with Polyangiitis Drug Revenue 2020-2025 ($

+357 96 030922
info@marketpublishers.com

millions)
Figure 37. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales 2020-2025 (K Pcs)
Figure 38. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue 2020-2025 ($ millions)
Figure 39. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2025
Figure 40. Americas Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2020-2025)
Figure 41. Americas Granulomatosis with Polyangiitis Drug Sales Market Share byType (2020-2025)
Figure 42. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2020-2025)
Figure 43. United States Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Region in 2025
Figure 48. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2020-2025)
Figure 49. APAC Granulomatosis with Polyangiitis Drug Sales Market Share byType (2020-2025)
Figure 50. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2020-2025)
Figure 51. China Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. India Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)

+357 96 030922
info@marketpublishers.com

Figure 56. Australia Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. ChinaTaiwan Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2025
Figure 59. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2020-2025)
Figure 60. Europe Granulomatosis with Polyangiitis Drug Sales Market Share byType (2020-2025)
Figure 61. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2020-2025)
Figure 62. Germany Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 63.France Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share byType (2020-2025)
Figure 69. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2020-2025)
Figure 70. Egypt Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 73.Turkey Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Granulomatosis with Polyangiitis Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis

+357 96 030922
info@marketpublishers.com

Drug in 2025
Figure 76. Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
Figure 77. Industry Chain Structure of Granulomatosis with Polyangiitis Drug
Figure 78. Channels of Distribution
Figure 79. Global Granulomatosis with Polyangiitis Drug Sales MarketForecast by Region (2026-2031)
Figure 80. Global Granulomatosis with Polyangiitis Drug Revenue Market ShareForecast by Region (2026-2031)
Figure 81. Global Granulomatosis with Polyangiitis Drug Sales Market ShareForecast byType (2026-2031)
Figure 82. Global Granulomatosis with Polyangiitis Drug Revenue Market ShareForecast byType (2026-2031)
Figure 83. Global Granulomatosis with Polyangiitis Drug Sales Market ShareForecast by Application (2026-2031)
Figure 84. Global Granulomatosis with Polyangiitis Drug Revenue Market ShareForecast by Application (2026-2031)

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Granulomatosis with Polyangiitis Drug Market Growth 2025-2031
Product link: https://marketpublishers.com/r/G752D5D30F93EN.html
Price: US$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G752D5D30F93EN.html